PL3076985T3 - Kompozycja zawierająca probiotyki z nadekspresją białka clpb do zastosowania w leczeniu otyłości - Google Patents

Kompozycja zawierająca probiotyki z nadekspresją białka clpb do zastosowania w leczeniu otyłości

Info

Publication number
PL3076985T3
PL3076985T3 PL14806649.1T PL14806649T PL3076985T3 PL 3076985 T3 PL3076985 T3 PL 3076985T3 PL 14806649 T PL14806649 T PL 14806649T PL 3076985 T3 PL3076985 T3 PL 3076985T3
Authority
PL
Poland
Prior art keywords
overexpression
obesity
treatment
composition containing
containing probiotics
Prior art date
Application number
PL14806649.1T
Other languages
English (en)
Inventor
Serguei Fetissov
Emmanuelle DE
Naouel TENNOUNE
Jonathan BRETON
Philippe CHAN-TCHI-SONG
Pierre Dechelotte
Romain LEGRAND
Original Assignee
Institut National De La Santé Et De La Recherche Médicale (Inserm)
Centre Hospitalier Universitaire De Rouen
Universite De Rouen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Santé Et De La Recherche Médicale (Inserm), Centre Hospitalier Universitaire De Rouen, Universite De Rouen filed Critical Institut National De La Santé Et De La Recherche Médicale (Inserm)
Publication of PL3076985T3 publication Critical patent/PL3076985T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
PL14806649.1T 2013-12-05 2014-12-04 Kompozycja zawierająca probiotyki z nadekspresją białka clpb do zastosowania w leczeniu otyłości PL3076985T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306673 2013-12-05
EP14306552 2014-10-02
PCT/EP2014/076611 WO2015082633A1 (en) 2013-12-05 2014-12-04 Bacterial influence on regulation of appetite via clpb protein mimicry of alpha-msh

Publications (1)

Publication Number Publication Date
PL3076985T3 true PL3076985T3 (pl) 2024-12-16

Family

ID=52007031

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14806649.1T PL3076985T3 (pl) 2013-12-05 2014-12-04 Kompozycja zawierająca probiotyki z nadekspresją białka clpb do zastosowania w leczeniu otyłości

Country Status (10)

Country Link
US (1) US20160313348A1 (pl)
EP (1) EP3076985B1 (pl)
JP (2) JP2017503768A (pl)
KR (1) KR102332078B1 (pl)
CN (1) CN106061491B (pl)
CA (1) CA2932488A1 (pl)
ES (1) ES2994101T3 (pl)
HR (1) HRP20241279T1 (pl)
PL (1) PL3076985T3 (pl)
WO (1) WO2015082633A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928379T3 (es) * 2014-10-02 2022-11-17 Inst Nat Sante Rech Med Composiciones farmacéuticas y alimenticias para inducir la saciedad y prolongar la saciedad en sujetos que lo necesitan
CA2988049A1 (en) 2015-06-05 2016-12-08 Targedys Pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof
EP3439684B1 (en) * 2016-04-05 2020-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Hafnia alvei based pharmaceutical and food compositions for inducing satiation and prolonging satiety
EP3385276A1 (en) * 2017-04-03 2018-10-10 Targedys Proteins derived from clpb and uses thereof
EP3384922A1 (en) 2017-04-03 2018-10-10 Targedys Brassicaceae protein extract and uses thereof
WO2020223609A1 (en) * 2019-05-01 2020-11-05 New York University Methods and compositions for sensitizing cancer cells to drug-induced apoptosis
EP4426325A1 (en) 2021-11-03 2024-09-11 Institut National de la Santé et de la Recherche Médicale (INSERM) Oxytocin-mimetic compositions and uses thereof
EP4176890A1 (en) 2021-11-03 2023-05-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Oxytocin-mimetic compositions and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003359A1 (en) * 1995-07-07 1997-01-30 Oravax, Inc. Helicobacter clpb
EP1981516B1 (en) * 2006-01-27 2018-08-08 DuPont Nutrition Biosciences ApS Use of probiotic microorganisms for the treatment and prevention of obesity and related disorders
EP2053122A1 (en) * 2007-10-23 2009-04-29 Nestec S.A. Stress tolerant bifidobacteria
WO2012011174A1 (ja) * 2010-07-22 2012-01-26 ビオフェルミン製薬株式会社 脂質代謝改善剤、脂質代謝改善作用増強剤、抗肥満剤及び抗肥満作用増強剤
KR20160101945A (ko) * 2013-12-05 2016-08-26 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) a-MSH의 ClpB 단백질 모방을 통한 숙주 급식 및 감정의 세균 영향

Also Published As

Publication number Publication date
HRP20241279T1 (hr) 2024-12-06
CA2932488A1 (en) 2015-06-11
ES2994101T3 (en) 2025-01-17
US20160313348A1 (en) 2016-10-27
EP3076985A1 (en) 2016-10-12
WO2015082633A1 (en) 2015-06-11
CN106061491B (zh) 2021-01-08
JP2017503768A (ja) 2017-02-02
KR20160101944A (ko) 2016-08-26
KR102332078B1 (ko) 2021-11-26
JP2019089815A (ja) 2019-06-13
JP6876732B2 (ja) 2021-05-26
CN106061491A (zh) 2016-10-26
EP3076985B1 (en) 2024-07-24
EP3076985C0 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
GB2516335B (en) The use of phytocannabinoids in the treatment of ovarian carcinoma
PT2991637T (pt) Fenfluramina para utilização no tratamento do síndrome de dravet
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
PL3489261T3 (pl) Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
SG11201601119XA (en) Survival benefit in patients with solid tumors with elevated c-reactive protein levels
GB201310909D0 (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
IL242483B (en) Preparations containing omomyc and their use for cancer treatment
SG11201509782TA (en) Compositions and methods for the treatment of diabetes and pre-diabetes
PL3044229T3 (pl) Peptydy do zastosowania w leczeniu zapalenia błony śluzowej jamy ustnej
EP3076985C0 (en) COMPOSITION COMPRISING PROBIOTICS CAPABLE OF OVEREXPRESSING CLPB PROTEIN FOR USE IN THE TREATMENT OF OBESITY
SG11201510150VA (en) Immunotherapy composition and use thereof
PL2910131T3 (pl) Kompozycja przeciwdziałająca zmęczeniu i jej zastosowanie
IL241418A0 (en) Improved methods of use for recombinant human secretoglobins
ZA201508050B (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
PL3074033T3 (pl) Związki do leczenia otyłości i sposoby ich zastosowania
PL2943215T3 (pl) Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu
SG11201601263WA (en) Recombinant microorganisms and methods of use thereof
GB201314623D0 (en) Novel mucinase for use in therapy or prophylaxis